Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 105,000 Shares

Key Points

• Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs at an average price of $75.42, totaling about $7.9 million. After the sale, he still held 927,504 shares, but his ownership fell by 10.17%.
• The company reported a narrower-than-expected loss for the latest quarter, posting EPS of -$0.45 versus the -$0.35 consensus estimate. Revenue came in at $59.88 million, above estimates and up 44.7% from a year earlier.
• Analysts remain generally constructive on ESTA, with a consensus rating of “Moderate Buy” and an average price target of $87.14. Several firms recently raised targets, though one rating was cut from buy to hold.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 105,000 shares of the company's stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company's stock, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, May 4th, Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock. The stock was sold at an average price of $70.48, for a total value of $546,290.48.
• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The stock was sold at an average price of $70.78, for a total value of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total value of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The shares were sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Trading Down 0.4%

Shares of ESTA stock traded down $0.26 during trading on Friday, hitting $71.77. 347,333 shares of the stock traded hands, compared to its average volume of 520,839. Establishment Labs Holdings Inc. has a 52-week low of $33.30 and a 52-week high of $83.31. The firm has a market capitalization of $2.11 billion, a P/E ratio of -48.17 and a beta of 1.12. The firm's fifty day moving average price is $65.27 and its 200-day moving average price is $66.59. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 202.78% and a negative net margin of 19.05%.The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. During the same period last year, the business earned ($0.70) EPS. Establishment Labs's revenue was up 44.7% compared to the same quarter last year. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ESTA has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Needham & Company LLC boosted their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, February 24th. Wall Street Zen lowered shares of Establishment Labs from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Citigroup reiterated a "neutral" rating on shares of Establishment Labs in a report on Wednesday. Finally, Stephens boosted their target price on Establishment Labs from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Establishment Labs currently has a consensus rating of "Moderate Buy" and an average price target of $87.14.

Institutional Trading of Establishment Labs

A number of institutional investors and hedge funds have recently bought and sold shares of ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company's stock worth $2,335,000 after purchasing an additional 9,557 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock valued at $1,105,000 after purchasing an additional 299 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Establishment Labs during the 2nd quarter worth approximately $651,000. Nebula Research & Development LLC increased its stake in Establishment Labs by 27.9% during the 2nd quarter. Nebula Research & Development LLC now owns 16,214 shares of the company's stock worth $692,000 after buying an additional 3,538 shares during the period. Finally, Sei Investments Co. lifted its holdings in Establishment Labs by 13.3% during the 2nd quarter. Sei Investments Co. now owns 48,428 shares of the company's stock worth $2,068,000 after buying an additional 5,668 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.